305 related articles for article (PubMed ID: 31015158)
21. Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external beam radiation therapy in 2216 patients.
Tanaka T; Yorozu A; Sutani S; Yagi Y; Nishiyama T; Shiraishi Y; Ohashi T; Hanada T; Saito S; Toya K; Shigematsu N
Brachytherapy; 2018; 17(5):799-807. PubMed ID: 29936128
[TBL] [Abstract][Full Text] [Related]
22. Anatomy-based inverse planning dose optimization in HDR prostate implant: a toxicity study.
Mahmoudieh A; Tremblay C; Beaulieu L; Lachance B; Harel F; Lessard E; Pouliot J; Vigneault E
Radiother Oncol; 2005 Jun; 75(3):318-24. PubMed ID: 16086913
[TBL] [Abstract][Full Text] [Related]
23. High dose rate brachytherapy boost for prostate cancer: Biochemical control and the impact of transurethral resection of the prostate and hydrogel spacer insertion on toxicity outcomes.
Chao M; Bolton D; Lim Joon D; Chan Y; Lawrentschuk N; Ho H; Spencer S; Wasiak J; Guerrieri M; Ow D; Troy A; Pham T; Sengupta S; Tan A; McMillan K; Koufogiannis G; Foroudi F; Ng M; Khoo V
J Med Imaging Radiat Oncol; 2019 Jun; 63(3):415-421. PubMed ID: 30908894
[TBL] [Abstract][Full Text] [Related]
24. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
[TBL] [Abstract][Full Text] [Related]
25. Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy.
Sutani S; Ohashi T; Sakayori M; Kaneda T; Yamashita S; Momma T; Hanada T; Shiraishi Y; Fukada J; Oya M; Shigematsu N
Radiother Oncol; 2015 Nov; 117(2):270-6. PubMed ID: 26318662
[TBL] [Abstract][Full Text] [Related]
26. Can high-dose-rate brachytherapy prevent the major genitourinary complication better than external beam radiation alone for patients with previous transurethral resection of prostate?
Luo HL; Fang FM; Kang CH; Chuang YC; Chiang PH
Int Urol Nephrol; 2013 Feb; 45(1):113-9. PubMed ID: 22972569
[TBL] [Abstract][Full Text] [Related]
27. Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer.
Strouthos I; Chatzikonstantinou G; Zamboglou N; Milickovic N; Papaioannou S; Bon D; Zamboglou C; Rödel C; Baltas D; Tselis N
Radiother Oncol; 2018 Aug; 128(2):301-307. PubMed ID: 29764692
[TBL] [Abstract][Full Text] [Related]
28. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
29. Toxicity and risk factors after combined high-dose-rate brachytherapy and external beam radiation therapy in men ≥75 years with localized prostate cancer.
Löser A; Beyer B; Carl CO; Löser B; Nagaraj Y; Frenzel T; Petersen C; Krüll A; Graefen M; Schwarz R
Strahlenther Onkol; 2019 May; 195(5):374-382. PubMed ID: 30390115
[TBL] [Abstract][Full Text] [Related]
30. A phase IB clinical trial of 15 Gy HDR brachytherapy followed by hypofractionated/SBRT in the management of intermediate-risk prostate cancer.
Den RB; Greenspan J; Doyle LA; Harrison AS; Peng C; Williams NL; Lallas CD; Trabulsi EJ; Gomella LG; Hurwitz MD; Leiby B; Dicker AP
Brachytherapy; 2020; 19(3):282-289. PubMed ID: 32217038
[TBL] [Abstract][Full Text] [Related]
31. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
32. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
[TBL] [Abstract][Full Text] [Related]
33. Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer.
Dhere VR; Fischer-Valuck BW; Goyal S; Liu Y; Morgan TM; Ghavidel E; Moghanaki DM; Hershatter BW; Patel PR; Jani AB; Godette KD; Rossi PJ; Patel SA
Brachytherapy; 2021; 20(6):1130-1138. PubMed ID: 34417136
[TBL] [Abstract][Full Text] [Related]
34. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103.
Taggar AS; Charas T; Cohen GN; Boonyawan K; Kollmeier M; McBride S; Mathur N; Damato AL; Zelefsky MJ
Brachytherapy; 2018; 17(2):251-258. PubMed ID: 29241706
[TBL] [Abstract][Full Text] [Related]
35. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
[TBL] [Abstract][Full Text] [Related]
36. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
37. Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial.
Gomez-Iturriaga A; Casquero F; Pijoan JI; Minguez P; Espinosa JM; Irasarri A; Bueso A; Cacicedo J; Buchser D; Bilbao P
Radiother Oncol; 2018 Feb; 126(2):278-282. PubMed ID: 29153462
[TBL] [Abstract][Full Text] [Related]
38. Fractionated high-dose-rate brachytherapy as monotherapy in prostate cancer: Does implant displacement and its correction influence acute and late toxicity?
Aluwini S; Busser WM; Baartman LE; Bhawanie A; Alemayehu WG; Boormans JL; Kolkman-Deurloo IK
Brachytherapy; 2016; 15(6):707-713. PubMed ID: 27364871
[TBL] [Abstract][Full Text] [Related]
39. Results of multiparametric transrectal ultrasound-based focal high-dose-rate dose escalation combined with supplementary external beam irradiation in intermediate- and high-risk localized prostate cancer patients.
Kovács G; Müller K; Soror T; Melchert C; Guo X; Jocham D; Merseburger A
Brachytherapy; 2017; 16(2):277-281. PubMed ID: 27964906
[TBL] [Abstract][Full Text] [Related]
40. High-dose-rate brachytherapy boost for prostate cancer: Analysis of dose-volume histogram parameters for predicting late rectal toxicity.
Chicas-Sett R; Farga D; Perez-Calatayud MJ; Celada F; Roldan S; Fornes-Ferrer V; Ibanez-Rosello B; Tormo A; Benlloch JM; Perez-Calatayud J
Brachytherapy; 2017; 16(3):511-517. PubMed ID: 28366276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
